الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 78 |  |  |
| | | from | 78 | | |
Abstract
New finding in the fields of cell biology and molecular genetics of cancer have revealed that the deregulation of cell cycle is a critical event for the onset of tumorigenesis. Uncontrolled cell proliferation is one of the main hallmark of cancer. The tumour cells have acquired damage to genes that are directly involved in regulating the cell cycle.
The aim of this study was to assess the prognostic significance of cyclin E in early stages of breast cancer and to evaluate the relation between cyclin E level and various clinico-pathological factors.
The study included 50 patients with pathologically proved breast cancer (stage I-III) after surgery where cyclin E expression was detected on paraffin blocks by immunohistochemical method. Levels of cyclin E were classified as high (score +3 and +4) and low (score 0, +1 and +2).
The patients’ age ranged from 30 to 65 years with a mean age of 48,0 years.
Twenty-nine patients (58%) included in the study had T2 (2-5 cm) tumours, fifteen patients (30%) had T3 (more than 5 cm) tumours and six patients (12%) had T1 (less than 2 cm) tumours.
Twelve patients (24%) had negative axillary lymph nodes while thirty-eight (76%) patients had positive axillary lymph nodes.
Determination of cyclin E expression was carried by immunohistochemical method. 52% of cases had high cyclin E level, while 48% of cases had low cyclin E level.
Concerning the relation between cyclin E and clinico-pathological parameters, cyclin E was found to have a significant relation with tumour size, lymph node statues and ER receptor status. On the other hand, it was found no significant relation between cyclin E and age or menopausal status of the patients.
One of the most important finding of our study is that the negative significant relation between cyclin E level and estrogen receptor status. Cyclin E over expression was associated with negative hormonal status, high cyclin E level was detected in 79.2% (19/24 patients) of estrogen receptor negative cases and in 26,9 (1/26 patients) of estrogen receptor positive cases.
The relapse free survival was assessed during the period one year of follow up. Ten cases out of the fifty cases relapsed during the period of follow up. It is noticed that all relapsed cases had high cyclin E level.